Table 1.
Clinicopathologic parameters of adenocarcinomas of the gastroesophageal junction
| All patients | ||
|---|---|---|
| Factors | (n = 40) | (%) |
| Age, mean (years) | 64 (35.0–80.4) | – |
| Sex | ||
| Male | 30 | (75.0) |
| Female | 10 | (25.0) |
| Tumor differentiation | ||
| 1 | 1 | (2.5) |
| 2 | 23 | (57.5) |
| 3 | 16 | (40.0) |
| cT before NCHT | ||
| 2 | 17 | (42.5) |
| 3 | 22 | (55.0) |
| 4 | 1 | (2.5) |
| cN before NCHT | ||
| 0 | 5 | (12.5) |
| 1 | 29 | (72.5) |
| 2 | 6 | (15.0) |
| pT | ||
| 1 | 8 | (20.0) |
| 2 | 11 | (27.5) |
| 3 | 19 | (47.5) |
| 4 | 2 | (5.0) |
| pN | ||
| 0 | 16 | (40.0) |
| 1 | 12 | (30.0) |
| 2 | 12 | (30.0) |
| Mandard TRG | ||
| 2 | 8 | (20.0) |
| 3 | 10 | (25.0) |
| 4 | 15 | (37.5) |
| 5 | 7 | (17.5) |
| Siewert classification | ||
| AEG I | 28 | (70.0) |
| AEG II | 6 | (15.0) |
| AEG III | 6 | (15.0) |
| NCHT regime | ||
| Cisplatin/5-fluoruacil | 21 | (52.5) |
| Oxaliplatin/capecitabine | 19 | (47.5) |
| Adjuvant chemotherapy | ||
| No | 29 | (72.5) |
| Yes | 11 | (27.5) |
| Surgical approach | ||
| Abdominal | 12 | (30.0) |
| Thoracoabdominal | 28 | (70.0) |
| ASA | ||
| 1 | 15 | (37.5) |
| 2 | 21 | (52.5) |
| 3 | 4 | (10.0) |
| ECOG before NCHT | ||
| 0 | 34 | (85.0) |
| 1 | 5 | (12.5) |
| 2 | 1 | (2.5) |
| ECOG before resection | ||
| 0 | 30 | (75.0) |
| 1 | 8 | (20.0) |
| 2 | 2 | (5.0) |
cT clinical tumor stage, cN clinical lymph node stage, pT pathological tumor stage, pN pathological lymph node stage, NCHT neoadjuvant chemotherapy, AEG adenocarcinoma of the gastroesophageal junction, ASA American Society of Anesthesiologists, ECOG Eastern Cooperative Oncology Group